Holen Sie sich die Stockscreener-App
220.43
0.80%
1.76
Handel nachbörslich:
219.41
-1.02
-0.46%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Spinal Cord Injury Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Kringle Pharma, Neuroplast, AbbVie, and Mitsubishi Tanabe Pharma America - Barchart.com
AbbVie Launches Love in Mind to Spotlight the Emotional Impact of Migraine on Romantic Relationships - Investing News Network
3 in 4 with migraine say attacks hurt their romantic lives - Stock Titan
Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
AbbVie (ABBV) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Why AbbVie Stock Trounced the Market in 2025 - Finviz
Aldeyra’s Dry Eye Drug Faces A Make-Or-Break FDA Call - Finimize
Taking The First Steps Towards Digitalizing Biopharma Development - Bioprocess Online
UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs - Benzinga
AbbVie's Irish operations in firing line as Trump targets Botox prices - Irish Examiner
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq
AbbVie Partners with Trump Administration to Enhance Access and Affordability - Intellectia AI
AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades' - Benzinga
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle - Benzinga
CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks - TipRanks
Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)? - Yahoo Finance
US names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - wkzo.com
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - Yahoo! Finance Canada
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks - Investing.com Canada
AbbVie stock rises as insurers crater and the Fed week kicks off - TechStock²
Citigroup Issues Pessimistic Forecast for AbbVie (NYSE:ABBV) Stock Price - MarketBeat
Citigroup Adjusts Price Target for AbbVie (ABBV) to $230, Mainta - GuruFocus
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
Is the Options Market Predicting a Spike in AbbVie Stock? - Yahoo Finance
J. Safra Sarasin Holding AG Purchases 62,723 Shares of AbbVie Inc. $ABBV - MarketBeat
Berenberg Grows More Confident in AbbVie (ABBV) on Skyrizi and Rinvoq Momentum - Finviz
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings - TechStock²
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings - TechStock²
How Recent Price Target Rethinks Are Rewriting The Story For AbbVie (ABBV) - Yahoo Finance
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vanguard Personalized Indexing Management LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Parthenon LLC - MarketBeat
AbbVie Inc. $ABBV Stake Cut by Lbp Am Sa - MarketBeat
AbbVie Inc. $ABBV Position Cut by Mutual of America Capital Management LLC - MarketBeat
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
AEGON ASSET MANAGEMENT UK Plc Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV): Investor Outlook and Potential 11.84% Upside with Strong Analyst Support - DirectorsTalk Interviews
Commerzbank Aktiengesellschaft FI Sells 39,586 Shares of AbbVie Inc. $ABBV - MarketBeat
Cullen Frost Bankers Inc. Has $88.49 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
West to Sell SmartDose 3.5mL System to AbbVie in $112.5M Deal - mychesco.com
AbbVie is a top dividend stock as drug pipelines drive payout hikes - thestreet.com
Mn Services Vermogensbeheer B.V. Has $155.25 Million Position in AbbVie Inc. $ABBV - MarketBeat
Resona Asset Management Co. Ltd. Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 18,081 Shares of AbbVie Inc. $ABBV - MarketBeat
UniSuper Management Pty Ltd Has $58.21 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Jennison Associates LLC - MarketBeat
Delta Financial Advisors LLC Purchases 4,830 Shares of AbbVie Inc. $ABBV - MarketBeat
TrueMark Investments LLC Lowers Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie stock rises as India rejects Venetoclax patent bid; ABBV traders eye Feb. 4 earnings - TechStock²
AbbVie Inc. $ABBV Shares Sold by Lockheed Martin Investment Management Co. - MarketBeat
Indian Patent Office rejects AbbVie patent bid for cancer drug Venetoclax; generics may enter market - domain-b.com
AbbVie Inc. $ABBV Shares Purchased by Strs Ohio - MarketBeat
AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next. - Barron's
AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week - TechStock²
ABBV vs. MRK: An Oncology-Immunology Showdown for Investors - Yahoo Finance
2 High-Yielding Dividend Stocks That Retirees Can Rely on for Recurring Income - Finviz
March 6th Options Now Available For AbbVie (ABBV) - Nasdaq
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AbbVie (ABBV) and Acadia Healthcare (ACHC) - The Globe and Mail
AbbVie Inc. $ABBV Shares Sold by Simplicity Wealth LLC - MarketBeat
AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
RemeGen scores out-licensing triple play with AbbVie deal - thebambooworks.com
Bernstein Sticks to Their Hold Rating for AbbVie (ABBV) - The Globe and Mail
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings - TechStock²
AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play - TechStock²
Price Over Earnings Overview: AbbVieAbbVie (NYSE:ABBV) - Benzinga
0.70%
1.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):